Katherine Stueland Sells 22,307 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 22,307 shares of GeneDx stock in a transaction on Monday, November 18th. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38. Following the completion of the sale, the chief executive officer now directly owns 60,011 shares in the company, valued at $4,221,173.74. This represents a 27.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40.
• On Monday, September 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87.

GeneDx Trading Down 2.3 %

NASDAQ WGS opened at $69.38 on Thursday. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 52 week low of $1.29 and a 52 week high of $89.11. The business’s fifty day simple moving average is $58.11 and its 200-day simple moving average is $38.91.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. GeneDx’s revenue was up 44.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.82) EPS. On average, equities research analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Craig Hallum raised their target price on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group raised their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company upped their target price on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. BTIG Research raised their price target on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, TD Cowen upped their price objective on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $59.33.

Hedge Funds Weigh In On GeneDx

Several large investors have recently modified their holdings of WGS. Acadian Asset Management LLC acquired a new position in shares of GeneDx in the 2nd quarter worth approximately $34,000. nVerses Capital LLC purchased a new stake in GeneDx in the second quarter valued at approximately $50,000. CWM LLC acquired a new position in GeneDx during the third quarter worth $89,000. SG Americas Securities LLC purchased a new position in shares of GeneDx during the third quarter worth $198,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of GeneDx in the third quarter valued at $220,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.